<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Battistoni A</submitter><funding>Ligue Contre le Cancer</funding><pagination>e006683</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10193056</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>11(5)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Metastases are the leading cause of mortality in many cancer types and lungs are one of the most common sites of metastasis alongside the liver, brain, and bones. In melanoma, 85% of late-stage patients harbor lung metastases. A local administration could enhance the targeting of metastases while limiting the systemic cytotoxicity. Therefore, intranasal administration of immunotherapeutic agents seems to be a promising approach to preferentially target lung metastases and decrease their burden on cancer mortality. From observations that certain microorganisms induce an acute infection of the tumor microenvironment leading to a local reactivating immune response, microbial-mediated immunotherapy is a next-generation field of investigation in which immunotherapies are engi</pubmed_abstract><journal>Journal for immunotherapy of cancer</journal><pubmed_title>Nasal administration of recombinant &lt;i>Neospora caninum&lt;/i> secreting IL-15/IL-15Rα inhibits metastatic melanoma development in lung.</pubmed_title><pmcid>PMC10193056</pmcid><funding_grant_id>LigueContreLeCancer2019</funding_grant_id><pubmed_authors>Mevelec MN</pubmed_authors><pubmed_authors>di Tommaso A</pubmed_authors><pubmed_authors>Lajoie L</pubmed_authors><pubmed_authors>Riviere C</pubmed_authors><pubmed_authors>Battistoni A</pubmed_authors><pubmed_authors>Dimier-Poisson I</pubmed_authors><pubmed_authors>Samimi M</pubmed_authors><pubmed_authors>Ducournau C</pubmed_authors><pubmed_authors>Lee GS</pubmed_authors><pubmed_authors>Moire N</pubmed_authors><pubmed_authors>Germon S</pubmed_authors><pubmed_authors>Hertereau L</pubmed_authors><pubmed_authors>Poupee-Beauge A</pubmed_authors><pubmed_authors>Epardaud M</pubmed_authors><pubmed_authors>Rieu J</pubmed_authors><pubmed_authors>Lantier L</pubmed_authors><pubmed_authors>Coenon L</pubmed_authors></additional><is_claimable>false</is_claimable><name>Nasal administration of recombinant &lt;i>Neospora caninum&lt;/i> secreting IL-15/IL-15Rα inhibits metastatic melanoma development in lung.</name><description>&lt;h4>Background&lt;/h4>Metastases are the leading cause of mortality in many cancer types and lungs are one of the most common sites of metastasis alongside the liver, brain, and bones. In melanoma, 85% of late-stage patients harbor lung metastases. A local administration could enhance the targeting of metastases while limiting the systemic cytotoxicity. Therefore, intranasal administration of immunotherapeutic agents seems to be a promising approach to preferentially target lung metastases and decrease their burden on cancer mortality. From observations that certain microorganisms induce an acute infection of the tumor microenvironment leading to a local reactivating immune response, microbial-mediated immunotherapy is a next-generation field of investigation in which immunotherapies are engi</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 May</publication><modification>2026-07-14T20:57:54.674Z</modification><creation>2026-06-24T03:07:06.94Z</creation></dates><accession>S-EPMC10193056</accession><cross_references><pubmed>37192784</pubmed><doi>10.1136/jitc-2023-006683</doi></cross_references></HashMap>